The Fort Worth Press - Study shows how fast kilos return after ending weight-loss drugs

USD -
AED 3.672501
AFN 64.000058
ALL 81.449762
AMD 370.780442
ANG 1.789884
AOA 917.999897
ARS 1392.874501
AUD 1.386472
AWG 1.8
AZN 1.69859
BAM 1.669697
BBD 2.01454
BDT 122.725158
BGN 1.668102
BHD 0.37765
BIF 2976
BMD 1
BND 1.275896
BOB 6.911331
BRL 4.959604
BSD 1.000226
BTN 94.881811
BWP 13.592996
BYN 2.822528
BYR 19600
BZD 2.011629
CAD 1.35834
CDF 2320.000136
CHF 0.781095
CLF 0.022861
CLP 899.749971
CNY 6.82825
CNH 6.829435
COP 3657.3
CRC 454.73562
CUC 1
CUP 26.5
CVE 94.450193
CZK 20.77575
DJF 177.719779
DKK 6.371505
DOP 59.502833
DZD 132.503944
EGP 53.639103
ERN 15
ETB 156.99989
EUR 0.85269
FJD 2.192102
FKP 0.736618
GBP 0.736155
GEL 2.680012
GGP 0.736618
GHS 11.200145
GIP 0.736618
GMD 72.999517
GNF 8774.999825
GTQ 7.641507
GYD 209.25239
HKD 7.834895
HNL 26.620134
HRK 6.4247
HTG 131.024649
HUF 309.302497
IDR 17334
ILS 2.94383
IMP 0.736618
INR 94.91055
IQD 1310
IRR 1314000.0001
ISK 122.610251
JEP 0.736618
JMD 156.725146
JOD 0.708977
JPY 156.889915
KES 129.149782
KGS 87.420496
KHR 4012.496617
KMF 419.999755
KPW 899.999976
KRW 1470.296134
KWD 0.30729
KYD 0.833543
KZT 463.288124
LAK 21980.000324
LBP 89550.000274
LKR 319.671116
LRD 183.874975
LSL 16.660217
LTL 2.95274
LVL 0.60489
LYD 6.349923
MAD 9.25125
MDL 17.233504
MGA 4149.999976
MKD 52.564485
MMK 2099.490131
MNT 3577.850535
MOP 8.070846
MRU 39.970119
MUR 47.030112
MVR 15.454964
MWK 1741.49797
MXN 17.44425
MYR 3.957503
MZN 63.910419
NAD 16.65992
NGN 1375.980106
NIO 36.710043
NOK 9.28854
NPR 151.803598
NZD 1.692835
OMR 0.384745
PAB 1.000201
PEN 3.507498
PGK 4.33875
PHP 61.241952
PKR 278.775014
PLN 3.61975
PYG 6151.626275
QAR 3.643504
RON 4.431403
RSD 100.106587
RUB 74.971307
RWF 1461.5
SAR 3.74998
SBD 8.04211
SCR 13.746323
SDG 600.494384
SEK 9.216399
SGD 1.27279
SHP 0.746601
SLE 24.592944
SLL 20969.496166
SOS 571.000185
SRD 37.458012
STD 20697.981008
STN 21.21
SVC 8.7523
SYP 110.524981
SZL 16.660258
THB 32.490193
TJS 9.381822
TMT 3.505
TND 2.88175
TOP 2.40776
TRY 45.190799
TTD 6.789386
TWD 31.629499
TZS 2605.00019
UAH 43.949336
UGX 3760.987334
UYU 39.889518
UZS 11950.000036
VES 488.942755
VND 26356
VUV 117.651389
WST 2.715189
XAF 560.041494
XAG 0.013202
XAU 0.000217
XCD 2.70255
XCG 1.80265
XDR 0.69563
XOF 559.999763
XPF 102.149753
YER 238.59682
ZAR 16.59045
ZMK 9001.199932
ZMW 18.67895
ZWL 321.999592
  • BCC

    -1.1400

    78.13

    -1.46%

  • CMSD

    0.1500

    23.28

    +0.64%

  • BCE

    0.1800

    23.96

    +0.75%

  • GSK

    -0.7000

    51.61

    -1.36%

  • AZN

    -2.6300

    184.74

    -1.42%

  • RIO

    0.1000

    100.58

    +0.1%

  • RBGPF

    0.5000

    63.1

    +0.79%

  • BP

    -0.9700

    46.41

    -2.09%

  • CMSC

    0.0600

    22.88

    +0.26%

  • NGG

    -1.0600

    88.48

    -1.2%

  • JRI

    -0.0100

    12.98

    -0.08%

  • BTI

    -0.0900

    58.71

    -0.15%

  • RELX

    -0.2400

    36.35

    -0.66%

  • VOD

    0.3500

    16.15

    +2.17%

  • RYCEF

    0.5500

    16.35

    +3.36%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: © AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

G.George--TFWP